Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.19 EUR
613.55 M EUR
36.99 B EUR
624.39 M
About Shanghai Pharmaceuticals Holding Co. Ltd. Class A
Sector
Industry
Website
Headquarters
Shanghai
Founded
1994
ISIN
CNE1000012B3
FIGI
BBG001PPCS90
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research and development, manufacture, distribution, and retail of pharmaceutical products. The company was founded on January 18, 1994 and is headquartered in Shanghai, China.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Shanghai Pharmaceuticals Holding Co. Ltd. Class H stocks are traded under the ticker S1R.
We've gathered analysts' opinions on Shanghai Pharmaceuticals Holding Co. Ltd. Class H future price: according to them, S1R price has a max estimate of 1.97 EUR and a min estimate of 1.10 EUR. Watch S1R chart and read a more detailed Shanghai Pharmaceuticals Holding Co. Ltd. Class H stock forecast: see what analysts think of Shanghai Pharmaceuticals Holding Co. Ltd. Class H and suggest that you do with its stocks.
Yes, you can track Shanghai Pharmaceuticals Holding Co. Ltd. Class H financials in yearly and quarterly reports right on TradingView.
Shanghai Pharmaceuticals Holding Co. Ltd. Class H is going to release the next earnings report on Oct 24, 2025. Keep track of upcoming events with our Earnings Calendar.
S1R earnings for the last quarter are 0.10 EUR per share, whereas the estimation was 0.10 EUR resulting in a 1.20% surprise. The estimated earnings for the next quarter are 0.04 EUR per share. See more details about Shanghai Pharmaceuticals Holding Co. Ltd. Class H earnings.
Shanghai Pharmaceuticals Holding Co. Ltd. Class H revenue for the last quarter amounts to 8.39 B EUR, despite the estimated figure of 8.59 B EUR. In the next quarter, revenue is expected to reach 8.71 B EUR.
S1R net income for the last quarter is 364.65 M EUR, while the quarter before that showed 169.28 M EUR of net income which accounts for 115.41% change. Track more Shanghai Pharmaceuticals Holding Co. Ltd. Class H financial stats to get the full picture.
Shanghai Pharmaceuticals Holding Co. Ltd. Class H dividend yield was 3.20% in 2024, and payout ratio reached 30.34%. The year before the numbers were 3.86% and 39.17% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 5, 2025, the company has 49.4 K employees. See our rating of the largest employees — is Shanghai Pharmaceuticals Holding Co. Ltd. Class H on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Shanghai Pharmaceuticals Holding Co. Ltd. Class H EBITDA is 1.20 B EUR, and current EBITDA margin is 4.12%. See more stats in Shanghai Pharmaceuticals Holding Co. Ltd. Class H financial statements.
Like other stocks, S1R shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Shanghai Pharmaceuticals Holding Co. Ltd. Class H stock right from TradingView charts — choose your broker and connect to your account.